February 2024
  • Fundraising
  • -
  • Equity capital markets

Implanet is a medical technology company that produces premium implants for orthopedic surgery.

Its business is centered around an innovative solution designed to improve the treatment of spinal pathologies, JAZZ®, which is complemented by the range of products offered by the company Orthopaedic & Spine Development, acquired in May 2021. Protected by 4 families of international patents, JAZZ® has received 510(k) regulatory clearance from the FDA in the United States, CE marking for Europe, and ANVISA authorization in Brazil.

In June 2022, IMPLANET entered into a commercial, strategic, and financial partnership with the Chinese group SANYOU MEDICAL, the second-largest Chinese manufacturer of medical devices for spine surgery. This partnership was notably materialized by SANYOU MEDICAL’s acquisition of a 30% stake in IMPLANET in October 2022, which was later increased to 41% in March 2023 following the exercise of share subscription warrants.

This partnership aims to distribute products manufactured by IMPLANET in China and to develop a completely new full range of a hybrid fixation system by pooling their expertise and research and development resources.

IMPLANET achieved a turnover of €7.4 million in 2023.

Following an initial issuance of shares with share subscription warrants in October 2022 amounting to €5.3 million, ATOUT CAPITAL assisted IMPLANET in structuring a new capital increase of €5.5 million. This operation, which maintained the preferential subscription right, allowed SANYOU MEDICAL to increase its stake in IMPLANET’s capital to 74.6%.

Thanks to this operation, IMPLANET has the means to continue its investments and asserts itself as a reference player in spine surgery, both in France and internationally, while consolidating its financial position.

Can we help you?
In both public and private companies, Atout Capital is able
to provide a unique transversal expertise with a 360 degree approach.